36 related articles for article (PubMed ID: 20622483)
21. FLT3 inhibition as a targeted therapy for acute myeloid leukemia.
Sanz M; Burnett A; Lo-Coco F; Löwenberg B
Curr Opin Oncol; 2009 Nov; 21(6):594-600. PubMed ID: 19684517
[TBL] [Abstract][Full Text] [Related]
22. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
Parcells BW; Ikeda AK; Simms-Waldrip T; Moore TB; Sakamoto KM
Stem Cells; 2006 May; 24(5):1174-84. PubMed ID: 16410383
[TBL] [Abstract][Full Text] [Related]
23. FLT3 tyrosine kinase as a target in acute leukemias.
Griffin JD
Hematol J; 2004; 5 Suppl 3():S188-90. PubMed ID: 15190306
[No Abstract] [Full Text] [Related]
24. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications.
Cheng Y; Paz K
IDrugs; 2008 Jan; 11(1):46-56. PubMed ID: 18175263
[TBL] [Abstract][Full Text] [Related]
25. Small molecule FLT3 tyrosine kinase inhibitors.
Levis M; Small D
Curr Pharm Des; 2004; 10(11):1183-93. PubMed ID: 15078134
[TBL] [Abstract][Full Text] [Related]
26. The clinical development of FLT3 inhibitors in acute myeloid leukemia.
Knapper S
Expert Opin Investig Drugs; 2011 Oct; 20(10):1377-95. PubMed ID: 21895538
[TBL] [Abstract][Full Text] [Related]
27. Management of Midostaurin-CYP3A4 Drug-Drug Interactions in Patients With Acute Myeloid Leukemia.
Schlafer D
Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365750
[No Abstract] [Full Text] [Related]
28. Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.
Hu B; Vikas P; Mohty M; Savani BN
Expert Rev Hematol; 2014 Apr; 7(2):301-15. PubMed ID: 24308526
[TBL] [Abstract][Full Text] [Related]
29. FMS-like tyrosine kinase 3 inhibitors: a patent review.
Lee J; Paek SM; Han SY
Expert Opin Ther Pat; 2011 Apr; 21(4):483-503. PubMed ID: 21323612
[TBL] [Abstract][Full Text] [Related]
30. FLT3 antibody-based therapeutics for leukemia therapy.
Li Y; Zhu Z
Int J Hematol; 2005 Aug; 82(2):108-14. PubMed ID: 16146840
[TBL] [Abstract][Full Text] [Related]
31. Zenarestat. FK 366, FR 74366, FR 901366.
Drugs R D; 2002; 3(4):235-7. PubMed ID: 12455199
[No Abstract] [Full Text] [Related]
32. [FLT3 kinase inhibitors for the treatment of acute leukemia].
Kiyoi H
Rinsho Ketsueki; 2010 Jun; 51(6):384-9. PubMed ID: 20622483
[No Abstract] [Full Text] [Related]
33. [Possibility of targeting FLT3 kinase for the treatment of leukemia].
Kiyoi H
Rinsho Ketsueki; 2005 Mar; 46(3):187-97. PubMed ID: 16447713
[No Abstract] [Full Text] [Related]
34. [New therapeutic option for leukemia patients, with FLT3/Aurora kinase inhibitor, KW-2449: strategy and comparison with other kinase inhibitors].
Shiotsu Y
Rinsho Ketsueki; 2008 Aug; 49(8):641-9. PubMed ID: 18800614
[No Abstract] [Full Text] [Related]
35. Can FLT3 inhibitors overcome resistance in AML?
Tam WF; Gary Gilliland D
Best Pract Res Clin Haematol; 2008 Mar; 21(1):13-20. PubMed ID: 18342808
[TBL] [Abstract][Full Text] [Related]
36. [Novel molecularly target therapies for leukemia].
Kiyoi H
Nihon Rinsho; 2007 Jan; 65 Suppl 1():611-6. PubMed ID: 17474469
[No Abstract] [Full Text] [Related]
[Previous] [New Search]